Semantic fluency predicts survival of memory clinic patients.

Multiple sclerosis (MS) is a chronic, inflammatory, neurodegenerative disease affecting an estimated 2.8 million people globally. Beyond sensory and motor symptoms, fatigue, cognitive difficulties, and emotional distress profoundly impact health-related quality of life (QoL). While disease-modifying drugs (DMDs) can reduce inflammation and relapses, they do not directly address these psychosocial and emotional aspects, which are sometimes termed ‘invisible symptoms’. Accordingly, guidelines increasingly recommend holistic approaches, including non-pharmacological approaches such as cognitive behavioural therapy (CBT) and health-behaviour interventions (e.g. physical activity, diet, and stress management) to improve QoL. Access to psychological and behavioural support is limited for many people with MS (pwMS) due to therapist shortages, geographical barriers, and disability-related constraints such as reduced mobility and fatigue. Digital therapeutics (DTx) may help by delivering evidence-based interventions remotely, although efficacy and safety need to be established for each program. Despite a growing DTx landscape, few interventions are designed to address the multi-domain needs of pwMS. is a DTx tailored for pwMS and is evaluated in this randomized controlled trial (RCT). The program's development and initial pilot testing confirmed its relevance, trustworthiness, and perceived utility for inspiring healthy lifestyle changes, as reported by pwMS and clinicians. Two previous RCTs investigated the program's efficacy, but with notable limitations. The first compared to web-adapted informational material, finding significant but small improvements in QoL, sick leave, and daily living activities. However, the trial suffered from high drop-out and, crucially, its active control group (CG) precluded comparison to standard treatment as usual (TAU). The second RCT compared to a non-personalized active psychoeducational program (‘dexilev’) in recently diagnosed pwMS and failed to meet its ambitious primary clinical endpoint (time to relapse or new lesion on magnetic resonance imaging), and no differential QoL effects emerged, possibly due to the sample's only minor baseline QoL impairments.